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Abstract
Background. Atherosclerosis is linked to inflammation. HDL protects against atherosclerotic 
cardiovascular disease, mainly by mediating cholesterol efflux and reverse cholesterol 
transport (RCT). The present study aimed to test the impact of acute inflammation as well 
as selected acute phase proteins on RCT with a macrophage-to-feces in vivo RCT assay 
using intraperitoneal administration of [3H]cholesterol-labeled macrophage foam cells. 
Results. In patients with acute sepsis, cholesterol efflux toward plasma and HDL 
were significantly decreased (P < 0.001). In mice, acute inflammation (75 µg/mouse 
lipopolysaccharide) decreased [3H]cholesterol appearance in plasma (P < 0.05) and 
tracer excretion into feces both within bile acids (−84%) and neutral sterols (−79%, each 
P < 0.001). In the absence of systemic inflammation, overexpression of serum amyloid 
A (SAA, adenovirus) reduced overall RCT (P < 0.05), whereas secretory phospholipase 
A2 (sPLA2, transgenic mice) had no effect. Myeloperoxidase injection reduced tracer 
appearance in plasma (P < 0.05) as well as RCT (−36%, P < 0.05). Hepatic expression of 
bile acid synthesis genes (P < 0.01) and transporters mediating biliary sterol excretion (P 
< 0.01) was decreased by inflammation. 
Conclusion. In conclusion, our data demonstrate that acute inflammation impairs 
cholesterol efflux in patients and macrophage-to-feces RCT in vivo in mice. Myeloperoxidase 
and SAA contribute to a certain extent to reduced RCT during inflammation but not 
sPLA2. However, reduced bile acid formation and decreased biliary sterol excretion might 
represent major contributing factors to decreased RCT in inflammation. 
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3.1 Introduction
Epidemiological studies established a strong inverse association between plasma HDL 
cholesterol levels and the risk of atherosclerotic cardiovascular disease (CVD).1, 2 A major 
anti-atherogenic activity of HDL is regarded to be reverse cholesterol transport (RCT), a 
process comprising removal of excess cholesterol from peripheral cells, most importantly 
macrophage foam cells in atherosclerotic lesions, and transport back to the liver for 
subsequent excretion into bile and feces.2, 3 Understanding the pathophysiological factors 
regulating RCT is therefore of prime importance. 
Inflammation is strongly linked to atherosclerosis.4-6 The atherosclerotic plaque itself 
is increasingly considered a site of chronic inflammation within the vessel wall.6, 7 In 
addition, markers of inflammation are elevated in plasma of patients with established 
atherosclerotic CVD, and circulating levels of several acute phase proteins (APPs) have 
been shown to possess a predictive value for future cardiovascular events.8, 9 Recently, 
it was also demonstrated that eliminating a large part of the hepatic acute phase 
response (APR) by knocking out the gp130 receptor on hepatocytes confers significant 
protection from atherosclerosis, indicating that APP might mechanistically contribute to 
the atherosclerotic process.10 Furthermore, inflammation impacts on HDL metabolism 
resulting in accelerated HDL catabolism and substantial remodeling of the HDL particle,11-13 
making it likely that these changes might translate into altered in vivo RCT. 
Therefore, the aim of the present study was to assess whether induction of the APR 
affects in vivo RCT and to dissect out the role of important APP that have been established 
to regulate HDL metabolism during an inflammatory response. Our data demonstrate 
that acute inflammation transiently reduces cholesterol efflux to plasma in patients 
with an APR and impairs macrophage-to-feces RCT in vivo in mice. Group IIA secretory 
phospholipase A2 (sPLA2) and myeloperoxidase (MPO), but not serum amyloid A (SAA), 
contribute to reduced cholesterol efflux toward plasma. However, although expression 
of sPLA2 in the absence of generalized inflammation did not affect macrophage-to-feces 
RCT, SAA overexpression and MPO infusion decreased in vivo RCT significantly. 
3.2 Materials and Methods
3.2.1 Patients
Consecutive patients admitted with acute sepsis to the intensive care unit (ICU) at 
Charité–Campus Benjamin Franklin in Berlin, Germany were included if they met 
established criteria for septic shock.14 Patients under 18 years of age, pregnant women, 
and patients with preexisting endocrine disorders were excluded. A first blood sample 
was obtained during a routine blood draw at admittance (d0) and a second blood sample 
was drawn at day 21 following complete clinical recovery, defined as SAPSII score below, 
35 no clinical signs of systemic infection, and no necessity for treatment at the ICU. Blood 
was immediately placed on ice and plasma was obtained and stored at −80°C until further 
analysis. Ten patients were included, eight matched healthy volunteers served as controls 
(for clinical details, see Table 3.1). The origin of infection in the patients was lungs (n = 
5), urinary tract (n = 4), and gallbladder (n = 1). Six patients had gram-negative and 2 
gram-positive infection; no bacteria could be isolated in two patients. Organ dysfunction 
included respiratory (n = 8), cardiovascular (n = 7), renal (n = 4), central nervous system 
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(n = 3), liver (n = 1), and hematologic (n = 1) failure. All patients were receiving inotropic 
drugs or vasopressors and required mechanical ventilation and hydrocortisone during 
the acute phase of sepsis. The study was approved by the local Ethics Committee and 
written informed consent for blood sampling was obtained from patients or their proxies.






Age (years) 59 ± 4 53 ± 2
BMI (kg/m2) 25.4 ± 0.9 23.5 ± 1.0
d 0 d 21
SAPSII score 63 ± 2 31 ± 1* n.d.
Total cholesterol (mg/dl) 109 ± 5 187 ± 9* 163 ± 9*
HDL cholesterol (mg/dl) 25 ± 2 48 ± 3* 47 ± 4*
Triglycerides (mg/dl) 139 ± 6 254 ± 12* 133 ± 11‡
SAA (µg/dl) 823 ± 99 18 ± 4* 3.0 ± 0.4*,‡
sPLA2 (ng/dl) 16,553 ± 2,072 242 ± 34
* 174 ± 8*
MPO (ng/ml) 365 ± 77 59 ± 9* 62 ± 9*
Values are means ± SEM. * Significantly different from d0 values, at least P < 0.05; ‡ significantly different from 
d21 values, at least P < 0.05.
3.2.2 Animals
C57BL/6J control mice were purchased from Charles River (Sulzfeld, Germany). The human 
group IIA sPLA2-transgenic mice expressing the human transgene under the control of the 
endogenous human promoter have been described previously.15 The sPLA2-transgenic 
line has been backcrossed to the C57BL/6J genetic background lacking the endogenous 
murine sPLA2 enzyme due to a frameshift mutation for > 14 generations. The animals 
were caged in animal rooms with alternating 12 h periods of light (from 7 AM to 7 PM) 
and dark (from 7 PM to 7 AM) with ad libitum access to water and mouse chow diet (Arie 
Blok, Woerden, The Netherlands). Animal experiments were performed in conformity 
with Public Health Service policy and in accordance with the national laws. All protocols 
were approved by the responsible ethics committees of the University of Groningen and 
the Landesamt für Gesundheit, Ernährung und technische Sicherheit Berlin (LAGETSI). 
3.2.3 Construction of recombinant adenoviruses
The human SAA1 cDNA was amplified from IL-6-treated HepG2 cells (ATCC via LGC 
Promochem, Teddington, UK) by PCR using specific primers according to the human 
sequence (NM_000331, GenBank) and subcloned into pcDNA3.1 (Invitrogen, Carlsbad, 
CA). Recombinant adenovirus (AdhSAA) was generated using the Adeno-X kit (Clontech, 
Mountain View, CA) according to the manufacturer’s instructions. The mouse CE/J SAA 
expressing adenovirus was kindly provided by Dr. Nancy Webb, University of Kentucky, 
Lexington, KY. An empty adenovirus (AdNull) was used as control.16 Recombinant 
adenoviruses were amplified and purified as described previously.17 For mouse 
experiments, a dose of 1 × 1011 particles/mouse of each of the respective adenoviruses 
was used. 
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3.2.4 In vivo reverse cholesterol transport studies
Wild-type C57BL/6J donor mice were injected intraperitoneally with 0.5 ml of 10% 
Brewer thioglycollate medium (Becton Dickinson, Le Point de Claix, France). On day 4 
after thioglycollate injection, peritoneal macrophages were harvested as described.18 
Macrophages were plated in RPMI 1640 medium (Invitrogen) supplemented with 10% 
FBS (HyClone, Logan, UT) and 1% penicillin/streptomycin (Invitrogen) and were allowed 
to adhere for 4 h at 37°C under 5% CO2 humidified air. Then nonadherent cells were 
removed by washing twice with PBS followed by loading of the macrophages with 50 μg/
ml acetylated LDL and 3 μCi/ml [3H]cholesterol (Perkin Elmer, Boston, MA) for 24 h. After 
washing twice with PBS, the macrophages were equilibrated for 18 h in RPMI 1640 medium 
containing 1% penicillin/streptomycin and 2% BSA (Sigma, St. Louis, MO). Immediately 
before injection, cells were harvested and resuspended in RPMI 1640 medium. As 
general procedure for in vivo macrophage-to-feces RCT studies, [3H]cholesterol-loaded 
macrophage foam cells were injected intraperitoneally into individually housed recipient 
mice. Plasma was collected at the indicated time points after macophage injection by 
retroorbital puncture and for the final blood draw by heart puncture. At the end of the 
experimental period, livers were harvested, snap-frozen in liquid nitrogen, and stored 
at −80°C until further use. Feces were collected continuously as indicated up to 48 h. 
Counts in plasma were assessed directly by liquid scintillation counting (Packard 1600CA 
Tri-Carb, Packard, Meriden, CT). To determine uptake of tracer into the liver and secretion 
into the feces, respective samples were processed as indicated below before scintillation 
counting. All obtained counts were expressed relative to the administered tracer dose.
Specifically, to study the effects of the APR on RCT, C57BL/6J mice were injected 
intraperitoneally with 75 μg lipopolysaccharide (LPS, Escherichia coli O111:B4, Sigma) 
in PBS, while controls received PBS injections shortly before receiving the labeled 
macrophage foam cells. LPS injection reduced food intake by 28% and feces production 
by 34%. For the subsequent experiment assessing the impact of SAA on macrophage-
to-feces RCT, C57BL/6J mice were injected with labeled macrophage foam cells on day 3 
after receiving AdSAA or the control adenovirus AdNull. To investigate the role of sPLA2 in 
RCT, sPLA2-transgenic mice were compared with C57BL/6J controls. To assess the impact 
of MPO on RCT, C57BL/6J mice received intravenously three consecutive injections in 6 
h intervals with either PBS (controls) or 50 µg/mouse purified MPO in 200 µl of 1 mM 
H2O2.
19 
3.2.5 Plasma lipid and lipoprotein analysis
Plasma total cholesterol and triglycerides were measured enzymatically using 
commercially available reagents (Wako Pure Chemical Industries, Neuss, Germany). To 
determine plasma HDL cholesterol levels, apolipoprotein (apo)B-containing lipoproteins 
were precipitated using 0.36% phosphotungstic acid (Sigma) and cholesterol content 
in the supernatant was determined as described above. HDL for efflux and cellular 
cholesterol uptake studies described below was isolated from patient plasma obtained at 
d0 and d21 by sequential ultracentrifugation (1.063 < d < 1.21) as described previously.15 
Pooled plasma samples from mice of the same experimental group were subjected to 
fast protein liquid chromatography (FPLC) gel filtration using a Superose 6 column (GE 
Healthcare, Uppsala, Sweden) as described.20 Samples were chromatographed at a flow 
rate of 0.5 ml/min, and fractions of 500 μl each were collected. Individual fractions were 
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assayed for cholesterol concentrations as described above. 
3.2.6 Determination of counts recovered within liver and feces
Counts within liver were determined following solubilization of the tissue (Solvable, 
Packard) exactly as previously reported.15 Counts recovered from a respective piece of 
liver were backcalculated to total liver mass. Fecal samples were dried, weighed, and 
thoroughly ground. Aliquots were separated into bile acid and neutral sterol fractions 
as previously published.16 Briefly, samples were first heated for 2 h at 80°C in alkaline 
methanol and then extracted three times with petroleum ether. In the top layer, counts 
within the neutral sterol fraction were determined by liquid scintillation counting, while 
counts incorporated into bile acids were assessed from the bottom layer. Counts recovered 
from the respective aliquots were related to the total amount of feces produced over the 
whole experimental period. 
3.2.7 In vitro efflux assays
Two sets of experiments were performed using either THP-1 cells or primary mouse 
peritoneal macrophages (see above). THP-1 human monocytes (ATCC via LGC Promochem) 
were grown in suspension culture in RPMI 1640 medium supplemented with 10% FBS, 
50 µM β-mercaptoethanol, and 1% penicillin/streptomycin until differentiation into 
macrophages by the addition of 100 ng/ml phorbol myristate acetate (PMA, Sigma). 
Differentiated THP-1 macrophages were loaded with 50 μg/ml acetylated LDL and 
3 μCi/ml [3H]cholesterol for 24 h followed by equilibration for 18 h as detailed above 
for peritoneal macrophages. Then cells were washed with PBS, and either 1% serum 
from patients and controls (THP-1 macrophages) or 50 µg protein/ml of isolated HDL 
(peritoneal macrophages) diluted in RPMI 1640 was added. After 24 h, the supernatant 
was taken off and radioactivity within the medium was determined by liquid scintillation 
counting. The cell layer was washed twice with PBS, then 0.1 M NaOH was added, plates 
were incubated for 30 min at room temperature, and the radioactivity remaining within 
the cells was assessed by liquid scintillation counting. Wells incubated with RPMI but 
without added serum or HDL were used as blanks to determine efflux not due to serum 
or HDL addition, and these values were subtracted from the respective experimental 
values. Efflux is given as the percentage of counts recovered from the medium in relation 
to the total counts present on the plate (sum of medium and cells). 
3.2.8 In vitro cholesterol uptake assays
HDL isolated from patient plasma by sequential ultracentrifugation (1.063 < d < 1.21) was 
labeled with the nonhydrolyzable trap label [3H]cholesteryl ether (Perkin Elmer) essentially 
as previously described.15 Cholesteryl ether behaves metabolically as cholesteryl ester;20 
however, by use of the ether bond resecretion by the cells is prevented. HepG2 cells 
were used as an established model for human hepatocytes and were cultured as 
detailed above except that 24 h before adding the labeled HDL preparations (50 µg HDL 
cholesterol/ml), 10% FBS was substituted by 10% lipoprotein-depleted serum. Labeled 
HDL preparations were then added to the cells in serum-free DMEM and incubations 
were continued for 6 h. Supernatants and cells were processed as detailed above for 
macrophages, and radioactivity within medium and cells was determined. Cellular uptake 
is expressed as the percentage of counts recovered from the cells in relation to the total 
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counts present on the plate (sum of medium and cells). Additional experiments were 
performed, in which HepG2 cells were treated for 24 h with a mixture of tumor necrosis 
factor-α (25 ng/ml), interleukin-1β (10 ng/ml) and interleukin-6 (500 pg/ml) (all from 
R and D Systems, Minneapolis, MN) and tracer uptake from healthy control HDL was 
determined essentially as outlined above. 
3.2.9 Western blotting
Expression of human SAA was checked by Western blot performed on plasma. Equal 
amounts of plasma were resolved by SDS-PAGE electrophoresis and blotted onto 
nitrocellulose (GE Healthcare Biosciences Corp., Piscataway, NJ). SAA was visualized 
using a commercially available monoclonal mouse anti-human SAA antibody (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA) followed by the appropriate HRP-conjugated 
secondary antibody (GE Healthcare, Chalfont St Giles, UK). Western blots for different 
hepatic transport proteins involved in the biliary secretion process were carried out on 
liver plasma membranes prepared essentially as described.21 Protein concentrations 
were determined with the bicinchoninic acid assay (Pierce Biotechnology, Inc., Rockford, 
IL). Equal amounts of protein were resolved by SDS-PAGE electrophoresis and blotted 
onto nitrocellulose. Abcg5 was visualized using a rabbit anti-mouse Abcg5 antibody 
(kindly provided by Dr. Albert Groen, University Medical Center Groningen, The 
Netherlands) and Abcb11 (Bsep) was detected using a rabbit anti-rat Abcb11 antibody 
(a kind gift from Dr Bruno Stieger, University Hospital Zurich, Switzerland), followed by 
the appropriate HRP-conjugated secondary antibody (GE Healthcare). HRP was detected 
using chemiluminescence (ECL, GE Healthcare). Blots were quantitated using the freely 
available ImageJ software adjusting the background for the area size of each band and 
subtracting it from the respective bands. Results were normalized for the average of the 
control mice. 
3.2.10 Determination of plasma SAA, sPLA2, and MPO levels
Commercially available ELISA kits were used according to the manufacturer’s instructions 
to respectively determine human SAA (Biosupply, Bradford, UK), mouse SAA (BioSource, 
Camarillo, CA), sPLA2 (Cayman Chemicals, Ann Arbor, MI), mouse MPO (Hycult 
Biotechnology b.v., Uden, The Netherlands), and human MPO (R and D Systems) levels 
in plasma. Please note that although plasma MPO levels obtained with the human and 
mouse MPO-specific systems are comparable, this is not given for the mouse versus the 
human SAA-specific ELISA systems. 
3.2.11 MPO purification
Human MPO was isolated as described previously.22 Briefly, isolated human neutrophils 
were dissolved in cetylmethyl ammonium bromide (Sigma) and sonicated. The extract 
was absorbed to a concanavalin A sepharose gel (Pharmacia, Uppsala, Sweden) and eluted 
with α-methyl-D-mannoside (Sigma). The eluate was further purified on a Sephadex 
G100 gel (Pharmacia). The final human MPO preparation had an optical density ratio 
428/280 of 0.78 and was not contaminated with proteinase 3, elastase or lactoferrin as 
determined by antigen specific ELISAs. Analysis by gel electrophoresis showed specific 
bands for human MPO at 15, 38, and 58 kDa. 
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3.2.12 Analysis of gene expression by real-time quantitative PCR
Total RNA from mouse livers was isolated using Trizol (Invitrogen) and quantified with 
a NanoDrop ND-100 UV-Vis spectrophotometer (NanoDrop Technologies, Wilmington, 
DE). cDNA synthesis was performed from 1 μg of total RNA. Real-time quantitative PCR 
was carried out on an ABI-Prism 7700 (Applied Biosystems, Foster City, CA) sequence 
detector with the default settings.21 PCR primers and fluorogenic probes were designed 
with the Primer Express Software (Applied Biosystems) and synthesized by Eurogentec 
(Seraing, Belgium). The mRNA expression levels presented were calculated relative to 
the average of the housekeeping gene cyclophilin and further normalized to the relative 
expression levels of the respective controls. 
3.2.13 Statistical analysis
Statistical analysis was carried out using the Statistical Package for the Social Sciences 
(SPSS, Inc., Chicago, IL). Values are expressed as means ± SEM. Paired or unpaired 
Student’s t-test was used as appropriate to assess statistical differences between groups. 
Statistical significance for all comparisons was assigned at P < 0.05. 
3.3 Results
3.3.1 Acute inflammation impairs macrophage cholesterol efflux to plasma and HDL in 
sepsis patients.
To assess the impact of acute inflammation in human patients on cholesterol efflux from 
macrophage foam cells, the first step in RCT, in vitro efflux experiments were performed. 
Blood samples were collected from sepsis patients on the day of admittance to the ICU 
(d0) and on day 21 following clinical recovery. Cholesterol efflux toward plasma was 
reduced by 73% in sepsis patients compared with matched healthy controls (P < 0.001, 
Figure 3.1A). After recovery, cholesterol efflux in the same patients improved significantly 
(P < 0.001) but was still lower than in controls (P < 0.05, Figure 3.1A). Because plasma HDL 
cholesterol levels are considerably lower in sepsis patients (Table 3.1), we next isolated 
HDL from patients and controls to delineate whether reduced efflux toward plasma might 
reflect decreased HDL levels or is due to altered acceptor properties of the HDL particle. 
Cholesterol efflux toward isolated HDL was also markedly impaired by acute sepsis 
compared with HDL from the same patients after recovery (P < 0.001, Figure 3.1B). Next, 
plasma levels of several acute phase proteins related to HDL metabolism were measured. 
Plasma SAA (P < 0.001), sPLA2 (P < 0.001), and MPO (P < 0.05) were significantly higher 
in sepsis patients than in controls (Table 3.1). After recovery from sepsis, plasma levels 
of sPLA2 and MPO returned to control values, whereas plasma levels of SAA at day 21 
remained still slightly elevated in patients compared with controls (P < 0.05, Table 3.1).
3.3.2 Acute inflammation decreases macrophage-to-feces RCT in vivo in mice.
Next we aimed to determine whether an acute inflammatory response would also 
translate into reduced RCT in vivo, using an established macrophage-to-feces RCT assay.23 
LPS injection increased plasma levels of SAA (24 h: 3685 ± 133, 48 h: 40 ± 3 μg/ml vs. 15 
± 2 μg/ml in the PBS controls) as well as MPO (48 h: 67 ± 4 vs. 145 ± 20 ng/ml, P < 0.01). 
Consistent with previous results,24 induction of the APR in mice did not result in significant 
changes in plasma total cholesterol (102 ± 7 vs. 112 ± 8 mg/dl, n.s.), HDL cholesterol (76 
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± 3 vs. 75 ± 10 mg/dl, n.s.) and non-HDL cholesterol (26 ± 3 vs. 37 ± 12 mg/dl, n.s.) levels 
48 h after LPS injection, reflected by only minor shifts in the plasma lipoprotein profile as 
determined by FPLC analysis (Figure 3.2A). On the other hand, plasma triglyceride levels 
increased significantly after LPS injection (40 ± 2 vs. 145 ± 36 mg/dl, P < 0.05). A single 
dose of LPS significantly decreased the movement of [3H]cholesterol toward plasma by 
33% at 6 h (P < 0.05, Figure 3.2B) and by 27% at 24 h after injection (P < 0.05), whereas 
counts within plasma were not different at 48 h compared with saline controls. [3H]
cholesterol tracer within liver was similar in both experimental groups (Figure 3.2C). In 
contrast, tracer recovery within feces was markedly reduced by LPS injection, both within 
the bile acid (P < 0.001) and the neutral sterol fraction (P < 0.001, Figure 3.2D). These 
data demonstrate, consistent with a previous report 25 that acute inflammation results in 
impaired RCT from macrophages to feces in vivo. 
3.3.3 Overexpression of human and mouse SAA has divergent effects on macrophage-
to-feces RCT in vivo.
SAA is an APP with apolipoprotein properties that preferentially associates with HDL.13, 24, 
26 To investigate whether SAA contributes to decreased RCT during the APR, human and 
mouse SAA were specifically overexpressed in the absence of generalized inflammation 
using recombinant adenoviruses. Human SAA overexpression did not impact on 
the plasma lipoprotein profile as revealed by FPLC analysis and also left plasma [3H]
cholesterol counts, liver counts, and tracer excretion into the feces essentially unchanged 
(Supplemental figure 3.I). Plasma levels of human SAA following recombinant adenovirus 
administration were 1020 ± 284 μg/dl at the 48 h time point. In contrast, mouse SAA 
overexpression increased LDL cholesterol in plasma (Figure 3.3A). Although plasma (Figure 
3.3B) and liver counts (Figure 3.3C) were not significantly affected, fecal [3H]cholesterol 
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Figure 3.1. Acute inflammation decreases macrophage cholesterol efflux in vitro toward plasma and HDL 
from sepsis patients. (A) Efflux from THP-1 macrophages loaded with [3H]labeled cholesterol and acetylated 
LDL toward 1% plasma for 24 h. (B) Efflux (24 h) from C57BL/6J thioglycollate-elicited peritoneal macrophages 
loaded with [3H]labeled cholesterol and acetylated LDL toward HDL (50 μg/ml) isolated by sequential 
ultracentrifugation. Experiments were performed as described under Materials and Methods. Data are given 
as means ± SEM. n = 10 for patients and n = 8 for controls. * indicates statistically significant differences from 
healthy controls (at least P < 0.05), and # indicates statistically significant differences from patients at day 21 (P 
< 0.001) as assessed by Student’s t-test. Day 0, patients with acute sepsis at the day of admittance to the ICU; 
day 21, the same patients following full recovery from sepsis 21 days after admittance.
tracer excretion was significantly decreased compared with control adenovirus-injected 
mice, indicating lower overall RCT in response to SAA overexpression (P < 0.05, Figure 
3.3D). Plasma mouse SAA levels in response to AdmSAA injection were 404 ± 96 μg/ml at 
the 48 h time point and 4.1-fold higher at the start of the experiment (0 h).
3.3.4 sPLA2 overexpression reduces cholesterol efflux toward plasma, but does not 
affect macrophage-to-feces RCT in vivo.
Similar to SAA, plasma sPLA2 levels are strongly elevated during human inflammation and 
sPLA2 has been shown to increase HDL catabolism in transgenic mice.
15, 27 To explore the 
effects of sPLA2 on RCT, we used transgenic mice specifically overexpressing human sPLA2 
in the absence of systemic inflammation. These mice had on average 4.7-fold higher 
plasma sPLA2 levels compared with the septic patients, and were on the C57BL/6J genetic 
background that lacks endogenous expression of the murine enzyme due to a frameshift 
mutation.15 Consistent with previously published data,15 HDL cholesterol levels were lower 
in sPLA2 transgenic mice as revealed by FPLC analysis (Figure 3.4A). sPLA2 overexpression 
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Figure 3.2. Acute inflammation impairs macrophage-to-feces reverse cholesterol transport in vivo in mice. 
C57BL/6J mice received intraperitoneal injections of either 75 μg LPS/mouse or saline and [3H]cholesterol-
loaded primary mouse macrophage foam cells as detailed in Materials and Methods and were followed for 48 
h. (A) FPLC cholesterol profiles of pooled plasma samples after injection of either saline or LPS. The relative 
elution position of the different lipoprotein subclasses is indicated. (B) [3H]cholesterol appearance in plasma 
obtained 6, 24, and 48 h after macrophage administration. (C) [3H]cholesterol tracer within liver 48 h after 
macrophage administration. (D) [3H]tracer appearance in total feces collected continuously from 0 to 48 h after 
macrophage injection and separated into the bile acid and neutral sterol fractions as indicated. Data in B, C, 
and D are expressed as percentage of the injected tracer dose and are presented as means ± SEM. n = 5–6 for 
each group. * indicates statistically significant differences from saline controls (at least P < 0.05) as assessed by 
Student’s t-test.
decreased the appearance of [3H]cholesterol in plasma 6 h (P < 0.05, Figure 3.4B), 24 
h (P < 0.05) and 48 h (P < 0.05) after macrophage injection. There was no significant 
difference in the recovery of [3H]cholesterol within liver between sPLA2 transgenic mice 
and C57BL/6J controls (Figure 3.4C). Fecal tracer excretion within the bile acid fraction 
was lower in sPLA2 overexpressing mice (P < 0.05, Figure 3.4D), whereas tracer excretion 
within the neutral sterol fraction and total RCT remained essentially unchanged. These 
results indicate that sPLA2 expression might contribute to decreased cholesterol efflux in 
response to acute inflammation; however, sPLA2 has no effect on overall macrophage-to-
feces RCT during the APR. 
3.3.5 MPO decreases macrophage-to-feces RCT in vivo.
Plasma MPO levels increase during the APR, and MPO-mediated oxidative modifications 
of HDL apolipoproteins, especially apoA-I, have been shown to decrease macrophage 
cholesterol efflux.28, 29 First, the effect of genetic MPO deficiency on RCT under conditions 
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Figure 3.3. Mouse SAA overexpression in the absence of systemic inflammation decreases macrophage-to-
feces reverse cholesterol transport in vivo in mice. On day 3 after injection with either the control adenovirus 
AdNull or the mouse CE/J SAA expressing adenovirus AdmSAA C57BL/6J mice received [3H]cholesterol-loaded 
primary mouse macrophage foam cells as detailed in Materials and Methods and were followed for 48 h. (A) 
FPLC cholesterol profiles of pooled plasma samples after injection of either AdNull or AdmSAA. The relative 
elution position of the different lipoprotein subclasses is indicated. (B) [3H]cholesterol appearance in plasma 
obtained 6, 24, and 48 h after macrophage administration. (C) [3H]cholesterol tracer within liver 48 h after 
macrophage administration. (D) [3H]tracer appearance in total feces collected continuously from 0 to 48 h after 
macrophage injection and separated into the bile acid and neutral sterol fractions as indicated. Data in B, C, and 
D are expressed as percentage of the injected tracer dose and are presented as means ± SEM. n = 8 for each 
group. * indicates statistically significant differences from AdNull injected controls (at least P < 0.05) as assessed 
by Student’s t-test.
of acute inflammation was tested. RCT in LPS-injected MPO knockout mice tended to be 
increased, but did not differ significantly from RCT in LPS-injected controls (Supplemental 
figure 3.II). However, murine neutrophils have only 10–20% of the MPO present in 
the respective human cells,30, 31 so that, especially in the context of a full-blown APR, 
the relative contribution of MPO might be too small to result in a significant effect. 
Therefore, we next tested the impact of injecting purified human MPO on RCT. Human 
MPO administration in the absence of an APR increased plasma levels (527 ± 41 ng/
ml, P < 0.001), resulted in discrete changes of the plasma lipoprotein profile (Figure 
3.5A), and in the formation of higher molecular mass aggregates of apoA-I upon SDS-
PAGE electrophoresis consistent with oxidative modification of the HDL particle (data 
not shown).32 Although plasma total cholesterol levels decreased significantly in MPO-
injected mice (90 ± 2 vs. 80 ± 2 mg/dl, P < 0.05), levels of HDL cholesterol (54 ± 2 vs. 48 ± 5 
mg/dl) as well as non-HDL cholesterol (21 ± 1 vs. 20 ± 2 mg/dl) did not differ significantly 
between groups. Cholesterol tracer recovery in plasma was reduced in MPO-injected 
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Figure 3.4. sPLA2 overexpression in the absence of systemic inflammation does not affect macrophage-to-feces 
reverse cholesterol transport in vivo in mice. C57BL/6J mice and sPLA2 transgenic mice received [
3H]cholesterol-
loaded primary mouse macrophage foam cells as detailed in Materials and Methods and were followed for 48 
h. (A) FPLC cholesterol profiles of pooled plasma samples in C57BL/6J mice and sPLA2 transgenic mice. The 
relative elution position of the different lipoprotein subclasses is indicated. (B) [3H]cholesterol appearance in 
plasma obtained 6, 24, and 48 h after macrophage administration. (C) [3H]cholesterol tracer within liver 48 h 
after macrophage administration. (D) [3H]tracer appearance in total feces collected continuously from 0 to 48 
h after macrophage injection and separated into the bile acid and neutral sterol fractions as indicated. Data in 
B, C, and D are expressed as percentage of the injected tracer dose and are presented as means ± SEM. n = 
5–6 for each group. * indicates statistically significant differences from wild-type controls (at least P < 0.05) as 
assessed by Student’s t-test.
mice at 6 h (Figure 3.5B) and 24 h (P < 0.05). Liver counts were not altered following 
MPO administration (Figure 3.5C). However, total [3H]cholesterol excretion into feces was 
significantly decreased in the mice injected with MPO compared with controls (P < 0.05, 
Figure 3.5D). This was mainly due to a decreased tracer recovery within fecal neutral 
sterols (P < 0.05), whereas tracer within fecal bile acids was not different between the 
experimental groups. These data show that MPO reduces macrophage-to-feces RCT in 
vivo, although quantitatively this effect is still substantially lower than the impact of the 
APR on RCT. 
3.3.6 Hepatic cholesterol uptake from acute phase HDL is not altered, but the hepatic 
gene expression profile in response to LPS indicates decreased biliary secretion. 
RCT comprises cholesterol efflux toward HDL in the periphery followed by hepatic uptake 
and excretion into bile. Because the action of three major secreted APPs does not fully 
explain decreased RCT during the APR, we next assessed whether hepatic cholesterol 
delivery from acute phase HDL might be impaired. Uptake of [3H]cholesteryl ether from 
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Figure 3.5. MPO impairs macrophage-to-feces reverse cholesterol transport in vivo in mice. C57BL/6J mice 
received [3H]cholesterol-loaded primary mouse macrophage foam cells and consecutive injections in 6 h 
intervals with either 50 µg/mouse purified MPO or vehicle for a total of 24 h as detailed in Materials and 
Methods. (A) FPLC cholesterol profiles of pooled plasma samples after injection of either vehicle or MPO. The 
relative elution position of the different lipoprotein subclasses is indicated. (B) [3H]cholesterol appearance in 
plasma obtained 6 and 24 h after macrophage administration. (C) [3H]cholesterol tracer within liver 24 h after 
macrophage administration. (D) [3H]tracer appearance in total feces collected continuously from 0 to 24 h after 
macrophage injection and separated into the bile acid and neutral sterol fractions as indicated. Data in B, C, 
and D are expressed as percentage of the injected tracer dose and are presented as means ± SEM. n = 6–7 for 
each group. * indicates statistically significant differences from vehicle controls (at least P < 0.05) as assessed 
by Student’s t-test.
acute phase HDL isolated from sepsis patients (d0) into HepG2 cells was not significantly 
different compared with HDL obtained after recovery (d21) (8.1 ± 0.7 vs. 7.2 ± 0.5%, 
n.s.). On the other hand, [3H]cholesteryl ether uptake from control HDL into HepG2 cells 
treated with a mixture of several pro-inflammatory cytokines was significantly increased 
(7.7 ± 0.3 vs. 9.8 ± 0.4%, P < 0.05). Because these data suggested that the hepatic 
cholesterol uptake step might not be impaired during inflammation, we next assessed 
the impact of the APR on the expression levels of key enzymes involved in conversion of 
cholesterol into bile acids as well as of transporters critical for the biliary secretion process. 
Hepatic mRNA expression of Cyp27a1, the initial enzyme in the alternative pathway of 
bile acid synthesis, was decreased by 67% in response to LPS (P < 0.001) whereas the 
expression of two other enzymes involved in bile acid synthesis, namely Cyp7a1, the rate-
limiting enzyme for the classic sterol-regulated pathway, and Cyp8b1, the key enzyme 
responsible for synthesis of cholic acid, was decreased, however, not significantly (Table 
3.2). Although Sr-b1 expression was not different between LPS-treated mice and saline 
controls, hepatic mRNA expression of Abcg5 (P < 0.05) and Abcg8 (P < 0.001), major 
transport proteins mediating biliary cholesterol secretion, was significantly decreased 
(Table 3.2). In addition, expression of Abcb11, an important bile acid export pump, was 
significantly reduced in response to LPS (P < 0.001), whereas the expression of Abcb4, 
which mediates biliary phospholipid secretion, was unaffected (Table 3.2). By Western 
blot (Supplemental figure 3.III) we confirmed that decreased hepatic mRNA expression 
during the APR also translates into reduced protein expression of Abcg5 by 65% (P < 0.05) 
and Abcb11 by 36% (P < 0.05). 
Taken together, these data indicate that coinciding with a substantial reduction in RCT 
acute inflammation significantly decreases the hepatic expression levels of key enzymes 
for bile acid synthesis as well as major transport proteins mediating the biliary secretion 
of bile acids and cholesterol. 






Cyp27a1 1.00 ± 0.07   0.33 ± 0.10*
Cyp7a1 1.00 ± 0.14 0.67 ± 0.40      
Cyp8b1 1.00 ± 0.21 0.53 ± 0.29
Sr-b1 1.00 ± 0.05 0.85 ± 0.15
Abcg5 1.00 ± 0.03   0.62 ± 0.08*
Abcg8 1.00 ± 0.05   0.34 ± 0.05*
Abcb11 1.00 ± 0.06   0.32 ± 0.11*
Abcb4 1.00 ± 0.07 0.76 ± 0.17
mRNA expression levels were determined by real-time quantitative PCR in livers of C57BL/6J mice 48 h after 
the administration of either saline or LPS as described in Materials and Methods. Results are normalized to the 
expression of the housekeeping gene cyclophilin and are expressed relative to the respective controls. Data are 
given as means ± SEM. * Significantly different from saline controls (at least P < 0.05)
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3.4 Discussion
The results of this study demonstrate that acute inflammation impairs cholesterol efflux 
to plasma and HDL in patients and macrophage-to-feces RCT in vivo in mice. sPLA2 and 
MPO but not SAA contribute to reduced cholesterol efflux toward plasma. Although sPLA2 
does not represent the underlying basis for the diminished macrophage-to-feces RCT 
during inflammation, mouse SAA and MPO cause a limited though significant decrease 
in overall RCT. 
Inflammation is closely linked to atherosclerotic CVD on several levels. Chronic 
inflammatory diseases such as rheumathoid arthritis are typically associated with an 
increased CVD risk in patients,4, 33 and chronic inflammation causally contributes to 
atherogenesis in vivo in mouse models.10 On the other hand, plasma levels of several 
APPs are elevated in patients with atherosclerotic CVD and have been shown to possess 
a predictive value for future cardiovascular events.8, 9 In addition, acute inflammation 
impacts on lipid metabolism resulting, in humans, in characteristic changes that resemble 
a pro-atherogenic lipoprotein profile as it is found in CVD patients, namely reduced plasma 
HDL cholesterol levels and increased plasma triglycerides.11 In mice, the drop in plasma 
HDL levels in response to an inflammatory stimulus does not occur as pronounced as in 
humans and we previously demonstrated using lipoprotein kinetics that the catabolic 
rates of HDL apolipoproteins as well as HDL cholesteryl ester remain largely unaffected 
by acute inflammation.12 However, in wild-type mice, inflammation results in altered 
tissue uptake of HDL and its components, namely significantly increased HDL holoparticle 
catabolism by the liver and increased selective uptake of HDL cholesteryl ester by the 
adrenals.12 The adrenals use HDL-derived cholesterol for the production of steroid 
hormones, which represent an important contributing factor to increased survival during 
an acute infection.34, 35 Therefore, redistribution of HDL cholesterol during the APR might 
have proven beneficial during evolution and several APPs might have evolved to aid in 
directing this process. In addition, the strong decrease in RCT that we observed in response 
to LPS injection might serve the general purpose of preventing cholesterol loss from the 
body. While our experiments were in progress, another study was published confirming 
the basic finding of reduced RCT in response to inflammatory stimuli.35 With regard to 
the impact of inflammation on cholesterol efflux from macrophages, it also has been 
shown previously that LPS and pro-inflammatory cytokines downregulate the expression 
of the two key cholesterol efflux transporters ABCA1 and ABCG1 in macrophages.36, 37 
Furthermore, acute phase HDL was demonstrated to not be able to support cholesterol 
efflux as well as normal HDL.38-40 However, the differential contribution of distinct 
components of the APR to these results has not been addressed thus far. 
In an attempt to delineate the impact of several APPs on RCT in vivo, we first investigated 
the effect of isolated overexpression of human and mouse SAA in the absence of an 
APR using recombinant adenoviruses. In plasma, SAA is primarily associated with HDL 
and can comprise the main apolipoprotein of acute-phase HDL.41, 42 Although earlier 
reports suggested that SAA might displace apoA-I from the HDL particle,11, 43 thereby 
potentially accelerating the HDL catabolic rate, overexpression of SAA in vivo by means 
of a recombinant adenovirus showed no effect on HDL catabolism.24 However, SAA 
might change the functional properties of the HDL particle. Although consistent with the 
apolipoprotein structure of SAA, this APP is able to mobilize cholesterol from cells;44, 45 SAA 
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in the context of the HDL particle might reduce cholesterol efflux from macrophages.38, 
46 Scavenger receptor class B type I (SR-BI) mediated selective uptake from SAA-enriched 
HDL is reduced and lipid-free SAA competes with HDL for SR-BI binding, also resulting in 
decreased selective uptake rates in vitro.47 On the other hand, selective uptake from acute 
phase HDL containing high levels of SAA was also reported to increase.38 As exemplified 
in our study, human and mouse SAA might possess different metabolic properties in the 
context of a murine HDL particle. Although overexpression of human SAA had no impact 
on tracer appearance in plasma or RCT in vivo, overexpression of mouse SAA decreased 
overall RCT. 
sPLA2 is an APP with a major effect on HDL catabolism. Transgenic overexpression of 
human sPLA2 in C57BL/6J mice, a strain lacking the endogenous murine sPLA2 enzyme 
due to a frameshift mutation, enhances the catabolic rates of HDL cholesteryl ester as 
well as HDL apoA-I resulting in decreased plasma HDL levels.12, 15, 27 In addition, sPLA2 
appears to be a key factor mediating decreased HDL cholesterol levels in response 
to inflammation. Although LPS injection into wild-type or human apoA-I transgenic 
mice lacking the endogenous murine sPLA2 enzyme has relatively little effects on HDL 
cholesterol levels, LPS administration to the respective models expressing a human sPLA2 
transgene that is responsive to inflammatory stimuli results in a pronounced decrease in 
plasma HDL cholesterol.12, 26 Furthermore, we have also previously established that sPLA2 
significantly enhances the redistribution of HDL cholesterol during inflammation, namely 
causing a strong increase in cholesteryl ester uptake into the adrenals,12 most likely due 
to increased susceptibility of HDL cholesteryl ester within sPLA2-modified HDL toward SR-
BI-mediated selective uptake.21 Although our data indicate that sPLA2 reduces cholesterol 
efflux toward plasma and might thereby explain the finding of decreased efflux toward 
plasma from sepsis patients, sPLA2 overexpression does not affect overall in vivo RCT. 
These results are especially interesting given that transgenic overexpression of human 
sPLA2 in mice accelerates atherosclerotic lesion development, even on a chow diet,
18, 48 
and that sPLA2 represents a strong CVD risk factor.
49-51 
MPO is an enzyme released from activated neutrophils and monocytes during an 
inflammatory response and has been implicated in the oxidative modification of HDL 
apolipoproteins resulting in dysfunctional HDL particles.52, 53 MPO-modified apoA-I and 
HDL have a reduced ability to elicit cholesterol efflux from macrophages,28, 29 consistent 
with the decrease in tracer appearance in plasma in response to MPO injection observed 
in our current study. In addition, MPO decreases the ability of apoA-I to activate LCAT.54 
On the other hand, hypochlorite modification of HDL mimicking the enzymatic activity 
of MPO has been shown to also decrease SR-BI-mediated selective uptake from oxidized 
HDL.32 These MPO-induced changes have been suggested to translate into decreased RCT; 
however, to our knowledge, the present study is the first to demonstrate significantly 
reduced RCT in response to MPO using an integrated physiologically relevant in vivo RCT 
assay. In humans, reduced RCT might therefore conceivably represent a contributing 
factor to the tight association between plasma MPO levels and risk of atherosclerotic CVD 
in several population studies.52, 54, 55 However, in mice the absence of MPO did not affect 
RCT in response to an APR, pointing toward a different mechanistic basis for decreased 
RCT during LPS-induced inflammation in the murine model. 
Of note, mice do not express the cholesteryl ester transfer protein that plays an important 
role in human lipoprotein metabolism and also in RCT. Cholesteryl ester transfer protein 
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expression is downregulated by inflammation,56, 57 which conceivably might represent an 
additional factor impacting on RCT in humans that was not addressed in the present 
study. 
As a general scheme, our results suggest that plasma APPs contribute to a certain extent 
to decreased RCT during an APR but do not fully explain it. Rather, APPs appear to be 
responsible for preserving the cholesterol content of peripheral tissues by reducing 
efflux and for mediating the redistribution of tissue cholesterol uptake from lipoproteins, 
especially HDL. The liver apparently serves in the setting of the APR as a gatekeeper to 
prevent loss of sterols from the body. This is, on the one hand, achieved by downregulation 
of the enzymes required for the conversion of cholesterol to bile acids 58, 59 and on the 
other hand, by decreasing the expression of Abcg5/g8 and Abcb11, responsible for the 
largest part of biliary secretion of cholesterol and bile acids, respectively. The decreased 
expression of Abcg5 and Abcb11 on the mRNA and protein level observed in our study 
is consistent with previously published findings 35, 37 and translates also into an actual 
reduction in biliary secretion rates of cholesterol and bile acids during the APR in mice 
(unpublished observations). 
In summary, our data demonstrate that reduced cholesterol efflux observed in patients 
with acute inflammation could at least partially be attributed to increased plasma levels 
of sPLA2 and MPO. Although in mice, sPLA2 did not influence overall RCT, murine SAA and 
MPO injection resulted in a limited decrease in RCT from macrophages to feces in vivo. 
However, also reduced biliary secretion of bile acids and cholesterol by the liver appears 
to be a major contributing factor to decreased macrophage-to-feces RCT during the APR. 
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Supplemental figure 3.I. Human SAA overexpression in the absence of systemic inflammation does not 
affect macrophage-to-feces reverse cholesterol transport in vivo in mice. On day 3 after injection with either 
the control adenovirus AdNull or the human SAA1 expressing adenovirus AdSAA C57BL/6J mice received [3H]
cholesterol-loaded primary mouse macrophage foam cells as detailed in Materials and Methods and were 
followed for 48 h. (A) Western blot analysis for SAA protein in plasma 48 h after macrophage injection. (B) FPLC 
cholesterol profiles of pooled plasma samples after injection of either AdNull or AdhSAA. The relative elution 
position of the different lipoprotein subclasses is indicated. (C) [3H]cholesterol appearance in plasma obtained 
6, 24, and 48 h after macrophage administration. (D) [3H]cholesterol tracer within liver 48 h after macrophage 
administration. (E) [3H]-tracer appearance in total feces collected continuously from 0 to 48 h after macrophage 
injection and separated into the bile acid and neutral sterol fractions as indicated. Data in C, D, and E were 
initially expressed as percentage of the injected tracer dose, further normalized to the respective values of the 
controls and are presented as means ± SEM. n = 6 for each group. * indicates statistically significant differences 
from AdNull injected controls (at least P < 0.05) as assessed by Student’s t-test.
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Supplemental figure 3.II. Macrophage-to-feces reverse cholesterol transport in vivo is not altered in MPO 
knockout mice. MPO knockout mice and C57BL/6J controls received intraperitoneal injections of 75 μg LPS/
mouse and then [3H]cholesterol-loaded primary mouse macrophage foam cells as detailed in Materials and 
Methods and were followed for 48 h. (A) FPLC cholesterol profiles of pooled plasma samples in either C57BL/6 
controls or MPO knockout mice. The relative elution position of the different lipoprotein subclasses is indicated. 
(B) [3H]cholesterol appearance in plasma obtained 6, 24, and 48 h after macrophage administration. (C) [3H]
cholesterol tracer within liver 48 h after macrophage administration. (D) [3H]-tracer appearance in total feces 
collected continuously from 0 to 48 h after macrophage injection and separated into the bile acid and neutral 
sterol fractions as indicated. Data in B, C, and D are expressed as percentage of the injected tracer dose and are 
presented as means ± SEM. n = 6-8 for each group. * indicates statistically significant differences from saline 
controls (at least P < 0.05) as assessed by Student’s t-test.
Supplemental figure 3.III. Acute inflammation decreases the hepatic protein expression of Abcg5 and Abcb11 
in mice. Hepatic protein expression for Abcg5 (A) and Abcb11 (B) was determined by Western blot in mice 48 h 
after injection with either LPS (75 μg/mouse) or saline as detailed in Materials and Methods.

